within Pharmacolibrary.Drugs.ATC.J;

model J01EA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00028333333333333335,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.029,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.094,
    k12             = 45,
    k21             = 45
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01EA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Iclaprim is a diaminopyrimidine antibiotic with activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is structurally related to trimethoprim and acts by inhibiting dihydrofolate reductase. Iclaprim has been investigated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia (HABP), but as of 2024, it is not approved for clinical use in the US or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with acute bacterial skin and skin structure infections receiving intravenous iclaprim.</p><h4>References</h4><ol><li><p>Kohlhoff, SA, &amp; Sharma, R (2007). Iclaprim. <i>Expert opinion on investigational drugs</i> 16(9) 1441–1448. DOI:<a href=&quot;https://doi.org/10.1517/13543784.16.9.1441&quot;>10.1517/13543784.16.9.1441</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17714029/&quot;>https://pubmed.ncbi.nlm.nih.gov/17714029</a></p></li><li><p>Andrews, J, et al., &amp; Wise, R (2007). Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. <i>The Journal of antimicrobial chemotherapy</i> 60(3) 677–680. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkm242&quot;>10.1093/jac/dkm242</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17623694/&quot;>https://pubmed.ncbi.nlm.nih.gov/17623694</a></p></li><li><p>Sincak, CA, &amp; Schmidt, JM (2009). Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. <i>The Annals of pharmacotherapy</i> 43(6) 1107–1114. DOI:<a href=&quot;https://doi.org/10.1345/aph.1L167&quot;>10.1345/aph.1L167</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19435963/&quot;>https://pubmed.ncbi.nlm.nih.gov/19435963</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01EA03;
